The DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index.
Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy
Abstract
Glycosylated pH-sensitive mesoporous silica nanoparticles (MSNs) of capecitabine (CAP) were developed for targeting colorectal cancer. The MSNs possessed an average pore diameter of 8.12 ± 0.43 nm, pore volume of 0.73 ± 0.21 cm 3/g, and particle size of 245.24 ± 5.75 nm. A high loading of 180.51 ± 5.23 mg/g attributed to the larger pore volume was observed. The surface of the drug-loaded MSNs were capped with chitosan-glucuronic acid (CHS-GCA) conjugate to combine two strategies viz. pH-sensitive, and lectin receptor mediated uptake. In vitro studies demonstrated a pH-sensitive and controlled release of CAP which was further enhanced in the presence of rat caecal content. Higher uptake of the (CAP-MSN)CHS-GCA was observed in HCT 116 cell lines. The glycosylated nanoparticles revealed reduction in the tumors, aberrant crypt foci, dysplasia and inflammation, and alleviation in the toxic features. This illustrated that the nanoparticles showed promising antitumor efficacy with reduced toxicity and may be used as a effective carrier against cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors
Haggar, F. A., & Boushey, R. P. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242458 · Cited by 2,018
Acidic extracellular microenvironment and cancer
Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-89 · Cited by 1,295
The Acidic Tumor Microenvironment as a Driver of Cancer
Boedtkjer, E., & Pedersen, S. F. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034627 · Cited by 1,293
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Narayan, R., Nayak, U. Y., Raichur, A. M., & Garg, S. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030118 · Cited by 987
Self-citation5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Walko, C. M., & Lindley, C. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 679
Strategies to Modify the Drug Release from Pharmaceutical Systems
(2015) · Elsevier eBooks · doi:10.1016/c2014-0-02342-8 · Cited by 623
Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property
Charnay, C., Bégu, S., Tourné‐Péteilh, C., Nicole, L., Lerner, D. A., & Devoisselle, J. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2003.12.007 · Cited by 517
Kumar, S., & Koh, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13056102 · Cited by 484
The acidic tumor microenvironment: a target for smart cancer nano-theranostics
Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2017) · National Science Review · doi:10.1093/nsr/nwx062 · Cited by 430
Flagged first, then by citations
2 of the 71 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Preparation and application of pH-responsive drug delivery systems
Ding, H., Tan, P., Fu, S., Tian, X., Zhang, H., Ma, X., Gu, Z., & Luo, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.056 · Cited by 645
An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine
Rastegari, E., Hsiao, Y., Lai, W.-Y., Lai, Y.-H., Yang, T., Chen, S., Huang, P., Chiou, S., Mou, C., & Chien, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071067 · Cited by 136
Djayanti, K., Maharjan, P., Cho, K. H., Jeong, S., Kim, M. S., Shin, M. C., & Min, K. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076349 · Cited by 129
Nanoparticle-based materials in anticancer drug delivery: Current and future prospects
Ajith, S., AlMomani, F. A., Elhissi, A. M. A., & Husseini, G. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21227 · Cited by 125
Pooresmaeil, M., Asl, E. A., & Namazi, H. (2021) · Journal of Alloys and Compounds · doi:10.1016/j.jallcom.2021.160992 · Cited by 114
Metadata
- Authors
- Narayan, R., Gadag, S., Cheruku, S. P., Raichur, A. M., Day, C. M., Garg, S., Manandhar, S., Pai, K. S. R., Suresh, A., Mehta, C. H., Nayak, Y., Kumar, N., & Nayak, U. Y.
- Affiliations
- Manipal Academy of Higher Education (IN)
- Indian Institute of Science Bangalore (IN)
- University of South Australia (AU)
- Corresponding author
- Nayak, Usha Yogendra
- ORCID
- Venue
- Carbohydrate Polymers
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 261
- Pages
- 117893
- ISSN
- 0144-8617 (ISSN-L)
- OpenAlex
- W3135707793
- Cited by
- 103
- References
- 71
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 21 · 2023: 17 · 2022: 19 · 2021: 8
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Carbohydrate Polymers (publishedVersion)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (acceptedVersion)
- NOT FOUND REPOSITORY (Indian Institute of Science Bangalore) (acceptedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Materials Chemistry › Mesoporous Materials and Catalysis
- Keywords
- mesoporous silica nanoparticles, capecitabine, colorectal cancer, pH-responsive drug delivery, receptor-targeted drug delivery, controlled drug release, HCT116 cells, tumor growth inhibition, aberrant crypt foci, dysplasia, inflammation
- MeSH terms
- Capecitabine, Animals, Cell Survival, Delayed-Action Preparations, Drug Carriers, Female, Humans, Hydrogen-Ion Concentration, Particle Size, Silicon Dioxide, Colorectal Neoplasms, Porosity, Drug Delivery Systems, Rats, Wistar, Coated Materials, Biocompatible, Glucuronic Acid, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Chitosan, Rats, Nanoparticles, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
